JP2020531414A - 併用療法 - Google Patents

併用療法 Download PDF

Info

Publication number
JP2020531414A
JP2020531414A JP2020507012A JP2020507012A JP2020531414A JP 2020531414 A JP2020531414 A JP 2020531414A JP 2020507012 A JP2020507012 A JP 2020507012A JP 2020507012 A JP2020507012 A JP 2020507012A JP 2020531414 A JP2020531414 A JP 2020531414A
Authority
JP
Japan
Prior art keywords
certain embodiments
substituents
enantiomers
optionally substituted
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020507012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531414A5 (OSRAM
Inventor
ピー． ゴールド，ダニエル
ピー． ゴールド，ダニエル
Original Assignee
エムイーアイ ファーマ，インク．
エムイーアイ ファーマ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エムイーアイ ファーマ，インク．, エムイーアイ ファーマ，インク． filed Critical エムイーアイ ファーマ，インク．
Publication of JP2020531414A publication Critical patent/JP2020531414A/ja
Publication of JP2020531414A5 publication Critical patent/JP2020531414A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020507012A 2017-08-14 2018-08-14 併用療法 Pending JP2020531414A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545427P 2017-08-14 2017-08-14
US62/545,427 2017-08-14
PCT/US2018/046742 WO2019036489A1 (en) 2017-08-14 2018-08-14 COMBINATION THERAPY

Publications (2)

Publication Number Publication Date
JP2020531414A true JP2020531414A (ja) 2020-11-05
JP2020531414A5 JP2020531414A5 (OSRAM) 2021-09-30

Family

ID=65362803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020507012A Pending JP2020531414A (ja) 2017-08-14 2018-08-14 併用療法

Country Status (14)

Country Link
US (2) US11351176B2 (OSRAM)
EP (1) EP3668507A4 (OSRAM)
JP (1) JP2020531414A (OSRAM)
KR (1) KR20200041358A (OSRAM)
CN (1) CN111212643A (OSRAM)
AU (1) AU2018318129A1 (OSRAM)
BR (1) BR112020002984A2 (OSRAM)
CA (1) CA3072476A1 (OSRAM)
IL (1) IL272560A (OSRAM)
MA (1) MA49921A (OSRAM)
MX (1) MX2020001727A (OSRAM)
RU (1) RU2020109775A (OSRAM)
SG (1) SG11202001258UA (OSRAM)
WO (1) WO2019036489A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013024907A2 (pt) 2011-03-28 2016-12-20 Mei Pharma Inc composto, composição farmacêutica, método para o tratamento, prevenção ou atenuação de um ou mais sintomas de um distúrbio, doença ou condição mediada por pi3k em um sujeito, método para modular a atividade enzimática de pi3k
KR20240097982A (ko) 2017-05-23 2024-06-27 메이 파마, 아이엔씨. 병용 요법
MA49921A (fr) 2017-08-14 2021-05-12 Mei Pharma Inc Polythérapie
BR112021002734A2 (pt) * 2018-08-14 2021-07-20 Mei Pharma, Inc. tratamento de linfoma folicular reincidente
JP2021534114A (ja) * 2018-08-14 2021-12-09 エムイーアイ ファーマ，インク． 併用療法
SG11202101450VA (en) * 2018-08-14 2021-03-30 Mei Pharma Inc Treatment of b cell malignancies
TW202038945A (zh) * 2018-12-21 2020-11-01 美商梅製藥公司 組合療法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509647A (ja) * 2011-03-28 2014-04-21 メイ プハルマ，インコーポレーテッド （α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物
JP2016505515A (ja) * 2012-11-02 2016-02-25 ティージー セラピューティクス インコーポレイテッド 抗ｃｄ２０抗体およびｐｉ３キナーゼ選択的阻害剤の組み合わせ
JP2017503001A (ja) * 2014-01-20 2017-01-26 ギリアード サイエンシーズ， インコーポレイテッド がんを処置するための療法

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711804A3 (de) 1994-11-14 1999-09-22 Ciba SC Holding AG Kryptolichtschutzmittel
JP3512911B2 (ja) 1995-07-11 2004-03-31 富士写真フイルム株式会社 紫外線吸収剤前駆体化合物、それを含有する感光性樹脂組成物及び画像形成方法
ES2213286T3 (es) 1997-07-24 2004-08-16 Zenyaku Kogyo Kabushiki Kaisha Compuestos heterociclicos y agente antitumoral que los contiene como ingredientes activos.
JPH11174638A (ja) 1997-12-08 1999-07-02 Konica Corp ハロゲン化銀カラー写真感光材料
KR100785363B1 (ko) 2000-04-25 2007-12-18 이코스 코포레이션 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제
CA2410514A1 (en) 2000-05-30 2001-12-06 Advanced Research & Technology Institute Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
DE10207037A1 (de) 2002-02-20 2003-08-28 Bayer Cropscience Gmbh 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
US7091343B2 (en) 2002-03-15 2006-08-15 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2003220300A1 (en) 2002-03-15 2003-09-29 Binch, Hayley Compositions useful as inhibitors of protein kinases
US7179826B2 (en) 2002-03-15 2007-02-20 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20040009981A1 (en) 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
CN1668759A (zh) 2002-05-17 2005-09-14 协和发酵工业株式会社 具有抗糖尿病作用的物质的探索方法
ES2389253T3 (es) 2002-10-25 2012-10-24 Zenyaku Kogyo Kabushiki Kaisha Compuestos heterocíclicos y agentes antitumorales que comprenden los mismos como ingrediente activo
JP4673218B2 (ja) 2002-11-21 2011-04-20 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ホスホチジルイノシトール（ｐｉ）３−キナーゼインヒビターとしての２，４，６−三置換ピリミジン、および癌の処置におけるその使用
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
GB2432834A (en) 2004-01-12 2007-06-06 Cytopia Res Pty Ltd Selective Kinase Inhibitors
DK1741714T3 (da) 2004-03-31 2013-04-15 Zenyaku Kogyo Kk Heterocyklisk forbindelse og middel mod ondartet turmor, der indeholder denne som aktiv ingrediens
EA011725B1 (ru) 2004-08-26 2009-04-28 Пфайзер Инк. Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
JP2008519850A (ja) 2004-11-10 2008-06-12 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２調節化合物
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
JP5089377B2 (ja) 2005-03-11 2012-12-05 全薬工業株式会社 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0525080D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525081D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US20070244110A1 (en) 2006-04-14 2007-10-18 Zenyaku Kogyo Kabushiki Kaisha Treatment of prostate cancer, melanoma or hepatic cancer
KR101402474B1 (ko) 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
MX2008013584A (es) 2006-04-26 2009-03-23 Genentech Inc Compuestos farmaceuticos.
AU2007282535B9 (en) 2006-08-08 2013-06-20 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as PI3K inhibitor and use thereof
WO2008032036A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US20100022534A1 (en) 2006-09-14 2010-01-28 Astrazeneca 2-benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
CN101595103A (zh) 2006-09-14 2009-12-02 阿斯利康(瑞典)有限公司 嘧啶衍生物
WO2008032089A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032077A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
WO2008032060A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
WO2008032091A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032041A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives having inhibitory activity against pi3k enzymes
WO2008032027A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
WO2008032072A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
JP2010503651A (ja) 2006-09-14 2010-02-04 アストラゼネカ アクチボラグ 増殖性障害の治療用のＰＩ３Ｋ及びｍＴＯＲ阻害剤としての２−ベンゾイミダゾリル−６−モルホリノ−フェニルピリミジン誘導体
EP2118087B1 (en) 2007-02-06 2012-03-28 Novartis AG Pi 3-kinase inhibitors and methods of their use
WO2008110891A2 (en) 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
CA2683152A1 (en) 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
KR20100042643A (ko) 2007-07-09 2010-04-26 아스트라제네카 아베 증식성 질환을 치료하기 위한 삼중치환된 피리미딘 유도체
CA2701581C (en) 2007-10-05 2016-12-20 S*Bio Pte Ltd Pyrimidine substituted purine derivatives
EP2209785A1 (en) 2007-10-05 2010-07-28 S*BIO Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
TWI482768B (zh) 2007-11-22 2015-05-01 Zenyaku Kogyo Kk 雜環化合物之非晶質體、含有其之固體分散體、藥劑及其製法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009093981A1 (en) 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
US20090192176A1 (en) 2008-01-30 2009-07-30 Wyeth 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
CL2009000241A1 (es) 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
US20110053907A1 (en) 2008-03-27 2011-03-03 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
CN104230831B (zh) 2008-05-23 2016-08-24 惠氏有限责任公司 作为PI3激酶和mTOR抑制剂的三嗪化合物
WO2009157880A1 (en) 2008-06-27 2009-12-30 S*Bio Pte Ltd Pyrazine substituted purines
WO2010005558A2 (en) 2008-07-07 2010-01-14 Xcovery, Inc. Pi3k isoform selective inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
CA2743642C (en) 2008-11-13 2017-09-19 Calistoga Pharmaceuticals, Inc. Therapies for hematologic malignancies
MX2011008444A (es) 2009-02-12 2011-09-06 Astellas Pharma Inc Derivado de heteroanillo.
BRPI1013600A2 (pt) 2009-03-27 2019-09-24 Pathway Therapeutics Inc "sulfonamidas de pirimidinila e benzintoazol de 1,3,5-triazinila e seu uso em terapia de câncer"
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
BRPI1009022A2 (pt) 2009-05-27 2016-03-08 Hoffmann La Roche "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
CA2772371A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
JP2012531436A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびそれらのｐｉ３ｋ活性阻害剤としての使用
EP2445886B1 (en) 2009-06-25 2016-03-30 Amgen, Inc 4-aminoquinoline derivatives as pi3k inhibitors
EP2445898A2 (en) 2009-06-25 2012-05-02 Amgen, Inc 4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors
CA2781865A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
CA2987503C (en) 2009-07-07 2019-02-26 Mei Pharma, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
AU2011290189B8 (en) 2010-08-10 2015-02-19 Astellas Pharma Inc. Heterocyclic compound
CA2819859A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
JP2014509648A (ja) 2011-03-28 2014-04-21 メイ プハルマ，インコーポレーテッド （α−置換シクロアルキルアミノ及びヘテロシクリルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、その医薬組成物、並びに増殖性疾患の治療におけるそれらの使用
WO2012135166A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
EP2723747A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP2014520161A (ja) 2011-06-22 2014-08-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2013006408A1 (en) 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013068075A1 (de) 2011-11-11 2013-05-16 Merck Patent Gmbh Verfahren zur herstellung von arylaminen
SI2882442T1 (sl) 2012-08-09 2021-11-30 Celgene Corporation Metode zdravljenja raka z uporabo 3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin- 2,6-diona
WO2014055647A1 (en) * 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
WO2014141129A2 (en) 2013-03-14 2014-09-18 Grueneberg Dorre A Novel methods, compounds, and compositions for inhibition of ros
EP2832358A1 (en) 2013-08-02 2015-02-04 Bionsil S.r.l. Pharmaceutical kit for use in the treatment of colon and colorectal cancer
CA2931431A1 (en) 2013-12-05 2015-06-11 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
US10227360B2 (en) 2014-02-19 2019-03-12 Piramal Enterprises Limited Compounds for use as GPR120 agonists
WO2015193740A2 (en) 2014-06-17 2015-12-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
DK3179991T3 (da) 2014-08-11 2021-12-06 Acerta Pharma Bv Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
US20170231995A1 (en) 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
SI3262071T1 (sl) 2014-09-23 2020-07-31 F. Hoffmann-La Roche Ag Način uporabe imunokonjugatov proti CD79b
CN107567443B (zh) 2014-12-24 2023-04-28 株式会社Lg化学 作为gpr120激动剂的联芳基衍生物
CN107922396B (zh) 2015-07-20 2022-08-05 建新公司 集落刺激因子-1受体(csf-1r)抑制剂
KR20180042356A (ko) 2015-08-24 2018-04-25 에피자임, 인코포레이티드 암 치료 방법
WO2017066705A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
EP3487878A4 (en) 2016-07-20 2020-03-25 University of Utah Research Foundation CAR-T CD229 LYMPHOCYTES AND METHODS OF USE
MA46285A (fr) 2016-09-19 2019-07-31 Mei Pharma Inc Polythérapie
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
KR20240097982A (ko) 2017-05-23 2024-06-27 메이 파마, 아이엔씨. 병용 요법
MA49921A (fr) 2017-08-14 2021-05-12 Mei Pharma Inc Polythérapie
EA202092154A1 (ru) 2018-03-21 2021-03-22 Мей Фарма, Инк. Комбинированная терапия
BR112021002734A2 (pt) 2018-08-14 2021-07-20 Mei Pharma, Inc. tratamento de linfoma folicular reincidente
SG11202101450VA (en) 2018-08-14 2021-03-30 Mei Pharma Inc Treatment of b cell malignancies
TW202038945A (zh) 2018-12-21 2020-11-01 美商梅製藥公司 組合療法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509647A (ja) * 2011-03-28 2014-04-21 メイ プハルマ，インコーポレーテッド （α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物
JP2016505515A (ja) * 2012-11-02 2016-02-25 ティージー セラピューティクス インコーポレイテッド 抗ｃｄ２０抗体およびｐｉ３キナーゼ選択的阻害剤の組み合わせ
JP2017503001A (ja) * 2014-01-20 2017-01-26 ギリアード サイエンシーズ， インコーポレイテッド がんを処置するための療法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD ADVANECES, vol. 1, no. 2, JPN6022028390, 2016, pages 122 - 131, ISSN: 0004822066 *
BLOOD, vol. Vo.120(21): 2907, JPN6022028388, 2012, ISSN: 0004822068 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 370, no. 11, JPN6022028389, 2014, pages 997 - 1007, ISSN: 0004822067 *

Also Published As

Publication number Publication date
CN111212643A (zh) 2020-05-29
US20200222415A1 (en) 2020-07-16
BR112020002984A2 (pt) 2020-08-11
KR20200041358A (ko) 2020-04-21
AU2018318129A1 (en) 2020-03-26
CA3072476A1 (en) 2019-02-21
US20220265673A1 (en) 2022-08-25
WO2019036489A1 (en) 2019-02-21
US11351176B2 (en) 2022-06-07
EP3668507A1 (en) 2020-06-24
SG11202001258UA (en) 2020-03-30
RU2020109775A (ru) 2021-09-16
MA49921A (fr) 2021-05-12
MX2020001727A (es) 2020-03-20
RU2020109775A3 (OSRAM) 2022-03-25
EP3668507A4 (en) 2021-05-12
IL272560A (en) 2020-03-31

Similar Documents

Publication Publication Date Title
CN106660991B (zh) 抗增殖化合物及其使用方法
JP2020531414A (ja) 併用療法
JP2021517116A (ja) 併用療法
JP2023001404A (ja) 併用療法
JP2023022081A (ja) 併用療法
TW202038945A (zh) 組合療法
JP2021534114A (ja) 併用療法
US20210196725A1 (en) Treatment of relapsed follicular lymphoma
US20210299134A1 (en) Treatment of b cell malignancies
HK40029947B (zh) 抗增殖化合物及其合成方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210812

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230421

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231002